Share on LinkedInShare on LinkedIn

ARTICLE · 20 OCTOBER 2011

Stem Cell Patents In The EU: To Be Or Not To Be?

The patent of Oliver Brüstle that is at stake relates to purified neural precursor cells and to processes for their production from embryonic stem cells.

NetherlandsIntellectual Property
John Allen
John Allen
Paul Van Dongen
Paul Van Dongen
Florence Verhoestraete
Florence Verhoestraete

Background

The patent of Oliver Brüstle that is at stake relates to purified neural precursor cells and to processes for their production from embryonic stem cells. Neural precursor cells may be used for the treatment of neural defects (like Parkinson's disease), which use is also claimed in the patent. According to the patent the embryonic stem cells from which the neural precursor cells are created are pluripotent, which means that they have the potential to develop into all kinds of cell types, but not into a complete human being. Only so-called totipotent cells are capable of developing into a human being.

Greenpeace is of the opinion that the subject matter of Brüstle's patent is not patentable because it would contravene public order and morality. Greenpeace argues that for the application of the invention it is necessary to use pluripotent embryonic stem cells, and that such stem cells can only be obtained by destroying an human embryo (although this latter

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from